Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches.
作者信息
Lahuerta Juan José, Paiva Bruno, Jiménez-Ubieto Ana, Sánchez-Pina José, Mateos María-Victoria, Bladé Joan, San-Miguel Jesús F
机构信息
Instituto de Investigación Sanitaria Hospital 12 de Octubre, Fundación PETHEMA, CIBERONC number CB16/12/00369, Madrid, Spain.
Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBERONC number CB16/12/00369, Pamplona, Spain.
出版信息
Blood Adv. 2021 Mar 9;5(5):1340-1343. doi: 10.1182/bloodadvances.2020003996.
Abstract
摘要
相似文献
1
Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches.多发性骨髓瘤治疗失败的早期检测与早期挽救干预：是时候采用新方法了。
Blood Adv. 2021 Mar 9;5(5):1340-1343. doi: 10.1182/bloodadvances.2020003996.
2
Multiple myeloma: Current advances and future directions.多发性骨髓瘤：当前进展与未来方向。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101155. doi: 10.1016/j.beha.2020.101155. Epub 2020 Feb 5.
3
Plasma cell dedifferentiation in refractory multiple myeloma.难治性多发性骨髓瘤中的浆细胞去分化
Br J Haematol. 2021 Apr;193(2):212. doi: 10.1111/bjh.17244. Epub 2021 Mar 26.
4
Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.多发性骨髓瘤：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2007 Apr;18 Suppl 2:ii44-6. doi: 10.1093/annonc/mdm032.
5
[Results, failures and perspectives in therapy of multiple myeloma].[多发性骨髓瘤治疗的结果、失败案例及前景]
Vopr Onkol. 2002;48(2):146-52.
6
Maintenance therapy in multiple myeloma.
Clin Adv Hematol Oncol. 2014 Feb;12(2):133-4.
7
[Cold agglutinin disease of IgA class as early manifestation of multiple myeloma and resolution after treatment with new anti-myeloma drugs].[IgA 类冷凝集素病作为多发性骨髓瘤的早期表现及新型抗骨髓瘤药物治疗后的缓解情况]
Med Clin (Barc). 2016 Dec 2;147(11):e63-e64. doi: 10.1016/j.medcli.2016.09.010. Epub 2016 Oct 27.
8
Multiple myeloma in the era of novel agents.
Semin Hematol. 2009 Apr;46(2):107-9. doi: 10.1053/j.seminhematol.2009.03.001.
9
Cardiovascular Complications of Novel Multiple Myeloma Treatments.新型多发性骨髓瘤治疗的心血管并发症
Circulation. 2016 Mar 1;133(9):908-12. doi: 10.1161/CIRCULATIONAHA.115.018351.
10
Multiple myeloma and systemic amyloidosis.
Int J Dermatol. 2008 Feb;47(2):165-7. doi: 10.1111/j.1365-4632.2008.03352.x.
引用本文的文献
1
MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study.微小RNA-665及其在多发性骨髓瘤药物反应和生存结局中的潜在作用：一项初步研究
Front Pharmacol. 2025 Apr 4;16:1465814. doi: 10.3389/fphar.2025.1465814. eCollection 2025.
2
Is there a Possible Association between Multiple Myeloma Relapse and Coronavirus Disease 2019 Vaccination? A Case Report.多发性骨髓瘤复发与2019冠状病毒病疫苗接种之间是否可能存在关联？一例病例报告。
J Res Pharm Pract. 2024 Sep 26;13(1):27-32. doi: 10.4103/jrpp.jrpp_21_24. eCollection 2024 Jan-Mar.
3
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.TOURMALINE-MM3 和-MM4 试验中 1280 例骨髓瘤患者维持治疗期间微小残留病灶动态变化与预后改善的关系。
Blood. 2023 Feb 9;141(6):579-591. doi: 10.1182/blood.2022016782.
4
Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.多发性骨髓瘤中的肿瘤缩小：新疗法的新概念
Front Oncol. 2022 Jan 14;11:800309. doi: 10.3389/fonc.2021.800309. eCollection 2021.
本文引用的文献
1
Newly Diagnosed Myeloma in 2020.2020年新诊断的骨髓瘤
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-15. doi: 10.1200/EDBK_280221.
2
Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond.初诊多发性骨髓瘤：当前的治疗策略、新出现的治疗方法及未来方向。
Expert Rev Hematol. 2020 Jun;13(6):669-686. doi: 10.1080/17474086.2020.1756258. Epub 2020 Apr 27.
3
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.OCEAN 研究：美法仑+地塞米松治疗复发/难治性多发性骨髓瘤的随机 III 期研究。
Future Oncol. 2020 Apr;16(11):631-641. doi: 10.2217/fon-2020-0024. Epub 2020 Mar 6.
4
Multiple Myeloma: Available Therapies and Causes of Drug Resistance.多发性骨髓瘤：现有治疗方法及耐药原因
Cancers (Basel). 2020 Feb 10;12(2):407. doi: 10.3390/cancers12020407.
5
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.基于新一代流式细胞术的多发性骨髓瘤微小残留病灶检测。
J Clin Oncol. 2020 Mar 10;38(8):784-792. doi: 10.1200/JCO.19.01231. Epub 2019 Nov 26.
6
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
7
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.环磷酰胺、硼替佐米与地塞米松适应性强化治疗对比未强化治疗用于新诊断的多发性骨髓瘤患者（骨髓瘤XI）：一项多中心、开放标签、随机、3期试验
Lancet Haematol. 2019 Dec;6(12):e616-e629. doi: 10.1016/S2352-3026(19)30167-X. Epub 2019 Oct 14.
8
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
9
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.新诊断多发性骨髓瘤完全缓解后的复发：缓解持续时间和复发模式的意义。
Leukemia. 2019 Mar;33(3):730-738. doi: 10.1038/s41375-018-0271-1. Epub 2018 Oct 15.
10
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.每周一次与每周两次卡非佐米给药治疗复发和难治性多发性骨髓瘤患者（A.R.R.O.W.）：一项随机、3 期研究的中期分析结果。
Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1.
Zotero 插件